Clinical correlation of nonalcoholic fatty liver disease in a Chinese taxi drivers population in Taiwan: Experience at a teaching hospital

BMC Research Notes

Jorn-Hon Liu⁵  Ming-Huei Chang²  Hui-Chuan Shih¹  Tzu-Han Lin²  Wei-Hsiu Chiu³  Tsung-Hung Chang¹  Tao-Hsin Tung⁴ 

[1] Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan, ROC;Department of Public Health, College of Medicine, Fu-Jen Catholic University, Taipei, Taiwan, ROC;Department of Obstetrics and Gynecology, Chung Shan Hospital, Taipei, Taiwan, ROC;Department of Nursing, Kang-Ning Junior College of Medical Care and Management, Taipei, Taiwan, ROC;Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC

关键词: gender difference;    taxi drivers;    prevalence;    nonalcoholic fatty liver disease;   

Others  :  1167251
DOI  :  10.1186/1756-0500-4-315

 received in 2011-02-01, accepted in 2011-08-31,  发布年份 2011

【 摘 要 】

Background

To explore any gender-related differences in the prevalence of conditions-associated with non-alcoholic fatty liver disease (NAFLD) among Taiwanese taxi drivers in Taipei, Taiwan.

Methods

We studied 1635 healthy taxi drivers (1541 males and 94 females) who volunteered for physical check-ups in 2006. Blood samples and ultrasound fatty liver sonography results were collected.

Results

The prevalence of NAFLD was 66.4% and revealed no statistically significant decrease with increasing age (p = 0.58). Males exhibited a greater prevalence of NAFLD than did females (67.5% vs 47.9%, p < 0.0001). Gender-related differences for associated factors were found. For males, hypertension, hyperuricemia, higher AST, higher ALT, hypertriglyceridemia, and higher fasting plasma glucose were significantly related to NAFLD. These conditions were not sigfinicantly related to NAFLD in females.

Conclusion

Several gender-related differences were noted for NAFLD among Taiwanese taxi drivers.

【 授权许可】

   
2011 Liu et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE: Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008, 28:13-24.
• [2]Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, et al.: Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase Levels: A role for insulin resistance and diabetes. Hepatology 2008, 48:792-798.
• [3]Yan H, Luo JY, Zhou XY: Epidemiological analysis of alcoholic and non-alcoholic fatty liver in Shanxi and Gansu province. Weichang Bingxue he Ganbing Xue Zazhi 2007, 16:347-350.
• [4]Ma JX, Zhou YJ, Chen PY, Nie YQ, Shi SL, Li YY: Epidemiological survey on fatty liver in rural area of Guangdong province. Zhongguo Gonggong Weisheng 2007, 23:874-876.
• [5]Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A: Asia-Pacific Working Party for NAFLD. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol 2007, 22:794-800.
• [6]Liu CM, Tung TH, Liu JH, Chen VT, Lin CH, Hsu CT, Chou P: A commumity-based epidemiological syudy of elevated serum alanine aminotransferase levels in Kinmen, Taiwan. World J Gastroenterol 2005, 11:1616-1622.
• [7]Dai HF, Shen Z, Yu CH, Zhang XC, Li YM: Epidemiology of fatty liver in an islander population of China: a population-based case-control study. Hepatobiliary Pancreat Dis Int 2008, 4:373-378.
• [8]Lazo M, Clark JM: The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008, 28:339-350.
• [9]Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatotology 2003, 37:1202-1219.
• [10]Williams R: Global changes in liver disease. Hepatology 2006, 44:521-526.
• [11]Fan JG, Farrell GC: Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009, 50:204-210.
• [12]Zhou YJ, Li yy, Nie YQ, Ma JX, Lu LG, Shi SL, et al.: Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol 2007, 13:6419-6424.
• [13]Fan JG, Zhu j, Li XJ, Chen L, Li L, Dai F, et al.: Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005, 43:508-514.
• [14]Fan JG: Steatohepatitis studies in China. Shijie Huaren Xiaohua Zazhi 2001, 9:6-10.
• [15]Sheth SG, Gordon FD, Chopra S: Nonalcoholic steatohepatitis. Ann Intern Med 1997, 126:137-145.
• [16]Carulli L, Lonardo A, Lombardini S, Marchesini G, Loria P: Gender, fatty liver and GGT. Hepatology 2006, 44:278-279.
• [17]Targher G, Bertolini L, Padovani R, et al.: Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007, 30:1212-1218.
• [18]Day CP: Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med 2006, 6:19-25.
• [19]McCullough AJ: Pathophysiology of non-alcoholic steatohepatitis. J Clin Gastroenterol 2006, 40:S17-S29.
• [20]Wong VW, Hui AY, Tsang SW, et al.: Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2006, 24:1215-1222.
• [21]Angulo P, Hui JM, Marchesini G, et al.: The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45:846-854.
• [22]Pendino GM, Mariano A, Surace P, et al.: Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology 2005, 41:1151-1159.
• [23]Pratt DS, Kaplan MM: Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000, 342:1266-1271.
• [24]Fan JG, Li f, Cai XB, Peng YD, Ao QH, Gao Y: The important of metabolic factors for the increasing prevalence of fatty liver in Shanghai factory workers. J Gastroenterol Hepatol 2007, 22:663-668.
• [25]Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, et al.: Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. J Gastroenterol Hepatol 2007, 22:1482-1489.
• [26]Alberti KGMM, Zimmet P, Shaw J: Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006, 23:469-480.
• [27]Hamaguchi M, Kojima T, Takeda N, et al.: The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005, 143:722-728.
• [28]Deurenberg P, Deurenberg-Yap M, Guricci S: Asians are different from Caucasians and from each other in their body mass index/body fat percent relationship. Obes Rev 2002, 3:141-146.
• [29]Loguercio C, Nardone G, Sicolo P, Cuomo R, Del Vecchio C, Budillon G: Intravenous load of fructose and fructose 1,6-diphosphate: effects on uricemia in patients with nonalcoholic liver disease. Am J Gastroenterology 1996, 91:559-564.
• [30]Bruckert E, Giral P, Ratziu V, Poynard T, Chapman MJ, Opolon P, Turpin G: A constellation of cardiovascular risk factors is associated with hepatic enzyme elevation in hyperlipidemic patients. Metabolism:Clinical & Experimental 2002, 51:1071-1076.
• [31]Strauss S, Gavish E, Gottlieb P, Katsnelson L: Interobserver and intraobserver variability in the sonographic assessment of fatty liver. Am J Roentgenol 2007, 189:W320-W323.
• [32]Chow SC, Shao J, Wang H: Sample Size Calculations in Clinical Research. Marcel Dekker. New York; 2003.
• [33]Fleiss JL, Levin B, Paik MC: Statistical Methods for Rates and Proportions. Third edition. John Wiley & Sons. New York; 2003.